Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 8/20 | 0.42 |
| ▸ | EGFR | P00533 | 5/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16978038 | 0.83 | MKNK2 (0.38) | MKNK2MKNK1IRAK4CYP1A2CYP2C9 | |
| SCHEMBL12984553 | 0.82 | MKNK2 (0.38) | MKNK2IRAK4 | |
| SCHEMBL19304206 | 0.78 | MKNK2 (0.35) | MKNK2MKNK1IRAK4CYP1A2CYP2C9 | |
| SCHEMBL12985414 | 0.75 | MKNK2 (0.33) | MKNK2EGFRIRAK4 | |
| SCHEMBL27729837 | 0.75 | CYP1A2 (0.36) | MKNK2EGFRIRAK4CYP1A2CYP2C9 | |
| SCHEMBL13195429 | 0.75 | IRAK4 (0.34) | MKNK2MKNK1IRAK4 | |
| SCHEMBL12985655 | 0.75 | MKNK2 (0.33) | MKNK2IRAK4 | |
| SCHEMBL30694603 | 0.75 | MKNK2 (0.45) | MKNK2EGFRMKNK1CYP1A2CYP3A4 | |
| SCHEMBL256370 | 0.75 | MKNK2 (0.45) | MKNK2EGFRMKNK1CYP1A2CYP3A4 | |
| SCHEMBL21167296 | 0.74 | APP (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11198699-B2 | Compounds targeting PRMT5 | ALIGOS THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20200317686-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10611777-B2 | Imidazopyridazine compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2020-04-07 | — | — | US | disclosed |
| US-20190127391-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LTD (CN) | 2019-05-02 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10208066-B2 | Imidazopyridazine compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-02-19 | — | — | US | disclosed |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| WO-2012137089-A1 | PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | PFIZER LIMITED (GB) | 2012-10-11 | — | — | WO | disclosed |
| US-8172873-B2 | Shape memory polymers | UNIVERSITY OF ROCHESTER (US) | 2012-05-08 | — | — | US | disclosed |
| US-8172873-B2 | Shape memory polymers | UNIVERSITY OF ROCHESTER (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110251364-A1 | Shape Memory Polymers | NATIONAL SCIENCE FOUNDATION | 2011-10-13 | — | — | US | disclosed |
| US-20110251364-A1 | Shape Memory Polymers | NATIONAL SCIENCE FOUNDATION | 2011-10-13 | — | — | US | disclosed |
| US-7935131-B2 | Shape memory polymers | UNIVERSITY OF ROCHESTER (US) | 2011-05-03 | — | — | US | disclosed |
| US-20110059976-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7767687-B2 | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors | BIOGEN IDEC MA INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080177303-A1 | Shape memory polymers | ROCHESTER, UNIVERSITY OF | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198699-B2 | Compounds targeting PRMT5 | PRMT5, PRMT1, PRMT6 | MKNK2 293/4885EGFR 2089/4885MKNK1 425/4885 |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | MKNK2 1527/4885EGFR 2508/4885MKNK1 1450/4885 |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | MKNK2 2520/4885EGFR 1801/4885MKNK1 2246/4885 |
| US-10208066-B2 | Imidazopyridazine compounds and their use | PIK3R5, PIK3CD, INPP5D | MKNK2 249/4885EGFR 826/4885MKNK1 254/4885 |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | MKNK2 1527/4885EGFR 2508/4885MKNK1 1450/4885 |
| US-20190127391-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | PIK3R5, PIK3CD, PIK3CB | MKNK2 237/4885EGFR 1148/4885MKNK1 251/4885 |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | MKNK2 1527/4885EGFR 2508/4885MKNK1 1450/4885 |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | DMPK, DTYMK, MUSK | MKNK2 58/4885EGFR 515/4885MKNK1 55/4885 |
| US-10611777-B2 | Imidazopyridazine compounds and their use | PIK3R5, PIK3CD, INPP5D | MKNK2 249/4885EGFR 826/4885MKNK1 254/4885 |
| US-20200317686-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | MKNK2 293/4885EGFR 2089/4885MKNK1 425/4885 |
| US-20110059976-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MKNK2 303/4885EGFR 1138/4885MKNK1 190/4885 |
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | MKNK2 293/4885EGFR 2089/4885MKNK1 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.